article · Egyptian Journal of Medical Human Genetics
Abstract Background Human Immunodeficiency Virus (HIV) remains a significant public health concern in Nigeria, characterized by the coexistence of diverse serotypes, mainly HIV-1 and HIV-2, each presenting unique therapeutic challenges. Understanding host immunogenetic variations is essential to improve treatment approaches. Objectives This study aimed to identify immunogenetic variations associated with HIV-1 and HIV-2, explore the relationship between specific Human Leukocyte Antigen (HLA) alleles and HIV susceptibility, assess cytokine gene polymorphisms in disease progression, and investigate implications for personalized treatment strategies among patients at a military hospital in Warri, Nigeria. Methods A cross-sectional study was conducted involving 300 HIV-infected individuals (200 HIV-1 and 100 HIV-2 patients) over 12 months. Genomic DNA was extracted from venous blood samples, and immunogenetic analyses included HLA typing, cytokine gene polymorphism assessments (TNF-α, IL-6, IL-10), and chemokine receptor genotyping (CCR5, CXCR4). Data were analyzed using SPSS version 26. Results HIV-1 patients exhibited a predominance of HLA-B35 and HLA-C07 alleles, while HLA-B*27 was less frequent. The TNF-α − 308G/A A allele was significantly associated with HIV-1 ( p < 0.05). Among HIV-2 patients, the G allele of IL-10−1082A/G was more prevalent, suggesting a role in replication control. The CCR5-∆32 variant was absent in this population. Conclusion This study underscores the influence of host genetic factors on HIV susceptibility and progression, with the TNF-α (−308G/A) polymorphism significantly associated with HIV-1 susceptibility, offering insights for tailored treatment approaches and informing public health strategies in Nigeria.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1186/s43042-025-00683-x
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.